权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A tumor suppressive therapy using selective cyclooxygenase-2 inhibitor for the patients with pancreas cancer

选择性环氧合酶2抑制剂对胰腺癌患者的肿瘤抑制治疗

基本信息

批准号：
16591318
负责人：
HIROOKA Yasuaki
金额：
$ 1.79万
依托单位：
National University Corporation Tottori University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2005
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16591318/
关键词：
pancreas cancer cholangio carcinoma COX2 inhibitor angiogenesis apoptosis Meloxicam 胆道癌

项目摘要

1.Relationship between COX2 and angiogenesisVEGF and Angiopoietin2 proteins were significantly expressed immunohistochemically in the high expression group of COX2 protein in 56 pancreatic cancer lesions. It was suggested that COX2 might be related to angiogenesis in the pancreatic cancer. However, in 45 choledochal cancer lesions, there were no relationship between COX2 and VEGF, Angiopoietin2.2.Relationship between COX2 and apoptosisBcl2 protein was significantly expressed and p-Akt protein was significantly supressed immunohistochemically in the high expression group of COX2 protein in 56 pancreatic cancer lesions. But, there was no relationship between COX2 and Apoptotic Index. We concluded that COX2 might not be supressed apoptosis in the pancreatic cancer.In 45 choledochal cancer lesions, there were no relationship between COX2 and apoptosis.3.COX2 inhibitor agent Meloxicam and anti-aneiogenetic, anti-apoptotic effectIn recurrenced pancreas cancer patients who received Gemcitabine and Meloxicam, anti-angiogenetic effect and anti-apoptotic effect were not observed.4.Clinical benefit responseIn recurrenced pancreas cancer patients who received Gemcitabine and Meloxicam, clinical benefit response was not observed by CT scan.

1.COX2与血管生成的关系COX2蛋白高表达组56例胰腺癌病变组织中vegf和Angiopoietin2蛋白免疫组化表达显著。提示COX2可能与胰腺癌血管生成有关。然而，在45例胆总管癌病变中，COX2与VEGF、血管生成素2.2无相关性。COX2蛋白高表达组56例胰腺癌病变组织中bcl2蛋白显著表达，p-Akt蛋白免疫组化明显抑制。但COX2与凋亡指数无相关性。我们得出结论，COX2可能不抑制胰腺癌细胞凋亡。在45例胆总管癌病变中，COX2与细胞凋亡无相关性。3 . COX2抑制剂美洛昔康与抗血管生成、抗细胞凋亡作用的比较，复发胰腺癌患者接受吉西他滨和美洛昔康治疗后，未观察其抗血管生成和抗细胞凋亡作用。临床获益反应在接受吉西他滨和美洛昔康治疗的复发胰腺癌患者中，CT扫描未观察到临床获益反应。

项目成果

期刊论文数量（12）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Expression of p-Akt and PTEN proteins for the patients with pancreatic cancer.

胰腺癌患者 p-Akt 和 PTEN 蛋白的表达。

DOI：
发表时间：
2004
期刊：
Proceeding of 42^<nd> Annual Meeting of Japan Society of Clinical Oncology 39・1
影响因子：
0
作者：
Li S;et al.;Ohgami yoshimi
通讯作者：
Ohgami yoshimi

Expression of p-Akt and PTEN Proteins Predicts the Survival of patients with pancreatic cancer.

p-Akt 和 PTEN 蛋白的表达可预测胰腺癌患者的生存。

DOI：
发表时间：
2006
期刊：
Yonago Acta medica 49・1
影响因子：
0
作者：
Tanaka T;et al.;Yoshimi Ozaki-Ohgami
通讯作者：
Yoshimi Ozaki-Ohgami

Expression of phospho-Akt and PTEN Proteins Predicts the Syrvival of Patient with Pancreatic Cancer

磷酸-Akt 和 PTEN 蛋白的表达预测胰腺癌患者的生存率

DOI：
发表时间：
2006
期刊：
Yonago Acta medica 49(1)
影响因子：
0
作者：
Ota H;Nagano H. et al.;Kobayashi M.;Yoshimi Ozaki-Ohgami
通讯作者：
Yoshimi Ozaki-Ohgami

膵臓癌におけるCOX-2発現とアポトーシスの検討

胰腺癌中COX-2表达和细胞凋亡的检测

DOI：
发表时间：
2005
期刊：
日本癌治療学会誌 40(1)
影响因子：
0
作者：
Damdinsuren B;Nagano H. et al.;岩本明美
通讯作者：
岩本明美

Expression of COX2 and apoptosis related proteins for the patients with pancreatic cancer.

胰腺癌患者COX2及凋亡相关蛋白的表达

DOI：
发表时间：
2005
期刊：
Proceeding of 43^<nd> Annual Meeting of Japan Society of Clinical Oncology 40・1
影响因子：
0
作者：
Tanaka T;et al.;Iwamoto Akemi
通讯作者：
Iwamoto Akemi